New Delhi, July 21 (IANS) India has approved its first vaccine for the prevention of dengue, a major step in strengthening the country’s response to one of its fastest-growing mosquito-borne diseases, an official statement said on Tuesday.The Central Drugs Standard Control Organisation (CDSCO) — under the Ministry of Health and Family Welfare — has granted marketing authorisation for Qdenga, a live, attenuated tetravalent dengue vaccine developed by Takeda GmbH, Germany. The vaccine will be im…
Latest Central Drugs Standard Control Organisation News & Updates
New Delhi, June 28 (IANS) The Ministry of Health and Family Welfare on Sunday announced that it has proposed amendments to the Medical Devices Rules, 2017 to simplify and accelerate the licensing process for medical devices, a move aimed at improving ease of doing business and ensuring quicker access to quality medical products in the country.The ministry has published a draft notification in the Official Gazette seeking public comments on the proposed changes, which are intended to streamline r…
New Delhi, March 17 (IANS) The Delhi High Court, on Tuesday, issued notice on a contempt petition alleging non-compliance with its earlier order directing Central Drugs Standard Control Organisation (CDSCO) to examine safety and regulatory concerns regarding the use of certain diabetes drugs for weight loss. A single-judge bench of Justice Sachin Datta sought responses from the Drugs Controller General of India (DCGI) and the Union Health Secretary Punya Salila Srivastava, and granted them four …
New Delhi, Feb 10 (IANS) AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to sell and distribute Durvalumab solution for infusion used in cancer treatment for an additional indication.In its latest stock exchange filing, the drug company said that through this approval, “Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or rec…